DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Plaque Psoriasis (Psoriasis Vulgaris) Overview
- Therapeutics Development
- Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview
- Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis
- Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies
- Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Investigation by Universities/Institutes
- Plaque Psoriasis (Psoriasis Vulgaris) Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies
- Plaque Psoriasis (Psoriasis Vulgaris) - Products under Investigation by Universities/Institutes
- Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development
- 3SBio Inc.
- AbGenomics International, Inc.
- Almirall, S.A.
- Amgen Inc.
- AstraZeneca Plc
- Avexxin AS
- Bionovis SA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Can-Fite BioPharma Ltd.
- Celgene Corporation
- Cellceutix Corporation
- Celltrion, Inc.
- Galectin Therapeutics, Inc.
- Genor BioPharma Co., Ltd.
- GlaxoSmithKline Plc
- Idera Pharmaceuticals, Inc.
- Invion Limited
- Johnson & Johnson
- Kadmon Corporation, LLC
- Kineta, Inc.
- Momenta Pharmaceuticals, Inc.
- Mycenax Biotech Inc.
- Novartis AG
- Oncobiologics, Inc.
- Pfizer Inc.
- Sucampo Pharmaceuticals, Inc.
- Sun Pharma Advanced Research Company Ltd.
- Takeda Pharmaceutical Company Limited
- TetraLogic Pharmaceuticals
- Therapeutic Proteins International, LLC
- UCB S.A.
- Valeant Pharmaceuticals International, Inc.
- XBiotech USA, Inc.
- Ziarco Pharma Ltd
For more information visit http://www.researchandmarkets.com/research/lx2pjx/plaque_psoriasis
